Physician profile
Robert A Ludwick
NPI 1043300999
$3,276.90
in general payments reported to CMS, 2019-2025
27 companies · $401 in 2025
The $401 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $696 · 2021: $579 · 2022: $533 · 2023: $264 · 2024: $253 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $808.97 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $331.94 | 2019-2025 | |
| Astellas Pharma US INC | $331.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $330.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.63 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $247.89 | 2019-2020 | |
| Glaxosmithkline, LLC. | $225.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $94.97 | 2022 | |
| Lilly USA, LLC | $83.51 | 2019-2023 | Mounjaro |
| Pfizer INC. | $72.56 | 2019-2021 | |
| Ardelyx, INC. | $66.14 | 2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $61.38 | 2020-2021 | |
| Corcept Therapeutics | $41.76 | 2024 | Korlym |
| Vanda Pharmaceuticals INC. | $31.67 | 2025 | Fanapt |
| Amgen INC. | $29.50 | 2025 | Repatha, Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $29.39 | 2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $20.77 | 2022 | |
| Amarin Pharma, INC. | $19.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.56 | 2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $15.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.16 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.80 | 2020 | |
| Biogen, INC. | $14.66 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.58 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $14.40 | 2024 | Capvaxive |
| Exact Sciences Corporation | $13.22 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ludwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.